Bright Minds Biosciences Inc. (CSE: DRUG)
DRUG trades on the Canadian Securities Exchange in Life Sciences, headquartered in British Columbia. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of November 13, 2026. US$ figures convert C$ at 1.4257 C$ per US$, the Bank of Canada daily rate for November 13, 2026. Close and returns: Yahoo Finance daily closes for DRUG.CN, last bar 2026-11-13, computed by MarginsX. Website: sociallinks: 40-F text ("our website").
Profile
| Field | Value |
|---|---|
| Ticker | DRUG on the Canadian Securities Exchange |
| Yahoo symbol | DRUG.CN |
| Sector | Life Sciences, Biotechnology |
| Headquarters | British Columbia |
| Listed | The TMX list gives no listing date |
| Listing type | TMX leaves listing type blank for long-listed issuers |
| Shares outstanding | 7,635,789 |
| Also listed on | No interlisting on the TMX list |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001827401 |
| Website | www.brightmindsbio.com |
| US listing | DRUG |
Returns
| Window | Return |
|---|---|
| 1 day | -0.8% |
| 1 week | +26.0% |
| 1 month | -56.1% |
| 3 months | -70.2% |
| 6 months | -71.8% |
| Year to date | -70.3% |
| 1 year | -60.2% |
| From 52-week high | -75.2% |
| 52-week range | C$26.00 to C$131.88 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
127 documents in 13 types. Each title links to the document at its source.
Annual financial statements (1)
| Document | Type | Filed |
|---|---|---|
| Audited consolidated financial statements of the Company and notes thereto for the year ended September 30, 2025, and 2024 together with the report… Period 2025-09-30 | Annual financial statements (40-F) | 2025-12-23 |
Interim financial statements (6)
| Document | Type | Filed |
|---|---|---|
| Condensed Interim Consolidated Financial Statements for the nine months ended June 30, 2026 and 2025 Period 2026-06-30 | Interim financial statements (6-K) | 2026-08-17 |
| Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2026 and 2025 Period 2026-03-31 | Interim financial statements (6-K) | 2026-05-20 |
| Condensed Interim Consolidated Financial Statements for the three months ended December 31, 2025 and 2024 Period 2025-12-31 | Interim financial statements (6-K) | 2026-02-13 |
| Condensed Interim Consolidated Financial Statements for the nine months ended June 30, 2025 and 2024 Period 2025-06-30 | Interim financial statements (6-K) | 2025-08-15 |
MD&A (7)
| Document | Type | Filed |
|---|---|---|
| Management's Discussion and Analysis for the twelve months ended September 30, 2025 Period 2025-09-30 | MD&A (annual) (40-F) | 2025-12-23 |
| Management's Discussion and Analysis for the Third Quarter Ended June 30, 2026 Period 2026-06-30 | MD&A (interim) (6-K) | 2026-08-17 |
| Management's Discussion and Analysis for the Second Quarter Ended March 31, 2026 Period 2026-03-31 | MD&A (interim) (6-K) | 2026-05-20 |
| Management's Discussion and Analysis for the First Quarter Ended December 31, 2025 Period 2025-12-31 | MD&A (interim) (6-K) | 2026-02-13 |
Annual information form (1)
| Document | Type | Filed |
|---|---|---|
| Annual Information Form of the Registrant for the twelve months ended September 30, 2025, dated December 23, 2025 Period 2025-09-30 | Annual information form (40-F) | 2025-12-23 |
News release (24)
| Document | Type | Filed |
|---|---|---|
| NEWS RELEASE | News release (6-K) | 2026-11-02 |
| to this Report of Foreign Private Issuer on Form 6-K are incorporated by reference into our (i) registration statement on Form F-3 (File No.… | News release (6-K) | 2026-10-01 |
| NEWS RELEASE | News release (6-K) | 2026-05-28 |
| to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No.… | News release (6-K) | 2026-01-09 |
Management information circular / proxy (5)
| Document | Type | Filed |
|---|---|---|
| to this Report of Foreign Private Issuer on Form 6-K are incorporated by reference into our (a) registration statement on Form F-3 (File No.… | Management information circular (6-K) | 2026-06-03 |
| Notice of Annual General Meeting of Shareholders to be held on March 31, 2026 | Notice of meeting (6-K) | 2026-06-03 |
| Notice and Access Notification to Shareholders | Notice of meeting (6-K) | 2026-06-03 |
| Notice of Annual General Meeting and Record Date | Notice of meeting (6-K) | 2026-06-02 |
Report of voting results (1)
| Document | Type | Filed |
|---|---|---|
| to this Report of Foreign Private Issuer on Form 6-K are incorporated by reference into our (i) registration statement on Form F-3 (File No.… | Report of voting results (6-K) | 2026-10-02 |
Prospectus (6)
| Document | Type | Filed |
|---|---|---|
| FORM 424B5 | Prospectus supplement (424B5) | 2026-01-09 |
| FORM 424B5 | Prospectus supplement (424B5) | 2026-01-07 |
| to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No.… | Prospectus (6-K/A) | 2025-11-17 |
| to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No.… | Prospectus (6-K) | 2025-11-17 |
Annual report (2)
| Document | Type | Filed |
|---|---|---|
| FORM 40-F Period 2025-09-30 | Annual report (40-F) (40-F) | 2025-12-23 |
| FORM 20-F Period 2024-09-30 | Annual report (20-F) (20-F) | 2024-12-31 |
Early warning / ownership (36)
| Document | Type | Filed |
|---|---|---|
| Schedule 13D amendment | Schedule 13D (SCHEDULE 13D/A) | 2026-07-02 |
| Schedule 13D amendment | Schedule 13D (SC 13D/A) | 2024-11-05 |
| Schedule 13D amendment | Schedule 13D (SC 13D/A) | 2024-11-05 |
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2026-11-16 |
Insider report (4)
| Document | Type | Filed |
|---|---|---|
| Form 3 | Form 3 (3) | 2024-10-17 |
| Form 4 | Form 4 (4) | 2026-04-30 |
| Form 4 | Form 4 (4) | 2024-11-06 |
| Form 4 | Form 4 (4) | 2024-10-17 |
Certification (18)
| Document | Type | Filed |
|---|---|---|
| Certification of Interim Filings - CEO | Certification (52-109F2) (6-K) | 2026-08-17 |
| Certification of Interim Filings - CFO | Certification (52-109F2) (6-K) | 2026-08-17 |
| Certification of Interim Filings - CEO | Certification (52-109F2) (6-K) | 2026-05-20 |
| Certification of Interim Filings - CFO | Certification (52-109F2) (6-K) | 2026-05-20 |
Other (16)
| Document | Type | Filed |
|---|---|---|
| Consent of De Visser Gray LLP, Independent Registered Public Accounting Firm Period 2025-09-30 | Consent (40-F) | 2025-12-23 |
| EXHIBIT 5.1 | Consent (F-3) | 2025-08-26 |
| EXHIBIT 23.1 | Consent (F-3) | 2025-08-26 |
| EXHIBIT 5.1 | Consent (F-3) | 2025-02-05 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
No CIRO halt notices for this company in our data.
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2024-11-19 | Equity | US$34.6M | US$34.6M | SEC EDGAR |
| 2024-10-22 | Option To Acquire, Security To Be Acquired | US$0 | US$12K | SEC EDGAR |
| 2024-05-03 | Equity, Option To Acquire, Security To Be Acquired, Other | US$0 | US$54K | SEC EDGAR |
| 2022-09-14 | Option To Acquire, Security To Be Acquired | US$0 | US$150K | SEC EDGAR |
| 2022-09-01 | Equity, Option To Acquire, Security To Be Acquired, Other | US$0 | US$220K | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| WSTR | WELLSTAR Technologies Corp. | TSXV | C$263.9M | -13.3% | Under a year of closes |
| CRRX | CareRx Corporation | TSX | C$213.7M | -3.0% | 0.0% |
| EDT | Spectral Medical Inc. | TSX | C$303.5M | -9.1% | -25.9% |
| TSND | TerrAscend Corp. | TSX | C$204.1M | -20.6% | -36.5% |
| MSCL | Satellos Bioscience Inc. | TSX | C$202.4M | -4.0% | +14.7% |
The app has the price chart, every filing, private raises and the full peer set for DRUG.
Open in the app